Effect of rosiglitazone and ramipril on macrovasculopathy in patients with type 2 diabetes: needs longer treatment and/or higher doses?

References

• StamlerJVaccaroONeatonJDWentworthDDiabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trialDiabetes Care19931624344448432214
   PubMed Web of Science ®Google Scholar
• RahmanSRahmanTIsmailAARahmanARADiabetes-associated macrovasculopathy: pathophysiology and pathogenesisDiab Obes Metab200796767780
   PubMed Web of Science ®Google Scholar
• ShargorodskySWainsteinGGavishELeibovitzZMatasDZimlichmanRTreatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitusAm J Hyperten2003168617622
   Web of Science ®Google Scholar
• PistroschFPassauerJFischerSFueckerKHanefeldMGrossPIn Type 2 diabetes rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose controlDiabetes Care200427248449014747233
   PubMed Web of Science ®Google Scholar
• LangenfeldMRForstTHohbergCPioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes: Results from a controlled randomized studyCirculation2005111192525253115883215
   PubMed Web of Science ®Google Scholar
• WatanabeITaniSAnazawaTKushiroTKanmatsuseKEffect of pioglitazone on arteriosclerosis in comparison with that of glibenclamideDiabetes Res Clin Pract200568210411015860237
   PubMed Web of Science ®Google Scholar
• LonnEYusufSDzavikVEffects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients with ramipril and vitamin E (SECURE)Circulation2001103791992511181464
   PubMed Web of Science ®Google Scholar
• KaiserTHeiseTNosekLEckersUSawickiPTInfluence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patientsJ Hypertens20062471397140316794490
   PubMed Web of Science ®Google Scholar
• HosomiNMizushigeKOhyamaHAngiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitusStroke20013271539154511441198
   PubMed Web of Science ®Google Scholar
• ManolisAJIraklianouSPittarasAArterial compliance changes in diabetic normotensive patients after angiotensin converting enzyme inhibition therapyAm J Hypertens2005181182215691612
   PubMed Web of Science ®Google Scholar
• RahmanSRahmanTIsmailAAIsmailSBNaingNNRahmanARAEffect of Rosiglitazone and ramipril on preclinical vasculopathy in newly diagnosed, untreated T2DM and IGT patients: one-year randomised, double-blind and placebo-controlled studyEur J Clin Pharmacol200763873374117565489
   PubMed Web of Science ®Google Scholar
• RahmanSRahmanTIsmailAAIsmailSBNaingNNRahmanARAEarly manifestation of macrovasculopathy in newly diagnosed never treated type II diabetic patients with no traditional CVD risk factorsDiabetes Res Clin Pract200880225325818249457
   PubMed Web of Science ®Google Scholar
• NissenSEWolskiKEffect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causesN Engl J Med2007356242457247117517853
   PubMed Web of Science ®Google Scholar
• MarreMLievreMChatellierGMannJFEPassaPMénardJEffects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study)BMJ2004328743849549914960504
   PubMed Web of Science ®Google Scholar
• HOPE Study InvestigatorsEffects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: result of HOPE study and MICRO-HOPE substudyLancet2000355920025325910675071
   PubMed Web of Science ®Google Scholar
• American diabetic associationStandards of medical care for patients with diabetes mellitus (position statement)Diabetes Care199821Suppl 1s23s31
   Google Scholar
• PhilipsLSGrunbergerGMillerEPatwardhamRRappaportEBSalzmanAOnce- and twice daily dosing of rosiglitazone improves glycemic control in patients with type 2 diabetesDiabetes Care200124230831511213884
   PubMed Web of Science ®Google Scholar
• HaffnerSMGreenbergASWestonWMChenHWilliamsKFreedMIEffect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients with Type 2 Diabetes MellitusCirculation2002106667968412163427
   PubMed Web of Science ®Google Scholar
• FonsecaVAValiquettTRHuangSMGhazziMNWhitcombRWTroglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study GroupJ Clin Endocrinol Metab1998839316931769745421
   PubMed Web of Science ®Google Scholar
• AronoffSRosenblattSBraithwaiteSPioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study GroupDiabetes Care200023111605161111092281
   PubMed Web of Science ®Google Scholar
• SilvioEInzucchiMDOral anti hyperglycemic therapy for type 2 diabetes scientific reviewJAMA2002287336037211790216
   PubMed Web of Science ®Google Scholar
• GirerdXGiannattasioCMoulinCSafarMManciaGLaurentSRegression of radial artery wall hypertrophy and improvement of carotid artery compliance after long-term antihypertensive treatment in elderly patientsJ Am Coll Cardiol1998315106410739562008
   PubMed Web of Science ®Google Scholar
• RomanMJAldermanMHPickeringTGDifferential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophyAm J Hypertens19981143873969607375
   PubMed Web of Science ®Google Scholar
• TropeanoAIBoutouyriePPannierBBrachial pressure–independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensivesHypertension2006481808616702490
   PubMed Web of Science ®Google Scholar
• BoschJYusufSPogueJUse of ramipril in preventing stroke: double blind randomised trialBMJ2002324733969970211909785
   PubMed Web of Science ®Google Scholar